Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Weisberg, P. Manley, S. Cowan-Jacob, A. Hochhaus, J. Griffin (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemiaNature Reviews Cancer, 7
R. Hehlmann, A. Hochhaus, M. Baccarani (2007)
Chronic myeloid leukaemiaThe Lancet, 370
BJ Druker, F Guilhot, SG O’Brien, I Gathmann, H Kantarjian, N Gattermann (2006)
IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med, 355
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.The New England journal of medicine, 355 23
J. Whiteley, S. Iyer, S. Candrilli, J. Kaye (2015)
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South KoreaCurrent Medical Research and Opinion, 31
G Guevara, JA González, DE Lopera, M González, JD Saavedra, JF Lobaton (2012)
Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in ColombiaColomb Med (Cali), 43
M. Romero, D. Chavez, M. Ríos, N. Alvis-Guzmán (2013)
Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.Biomedica : revista del Instituto Nacional de Salud, 34 1
H. Henk, M. Woloj, M. Shapiro, J. Whiteley (2015)
Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.Clinical therapeutics, 37 1
B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. Ford, N. Lydon, H. Kantarjian, R. Capdeville, Sayuri Ohno-Jones, C. Sawyers (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.The New England journal of medicine, 344 14
G. Guevara, J. González, D. Lopera, Manuel González, J. Saavedra, J. Lobaton, J. Duque (2012)
Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in ColombiaColombia Médica : CM, 43
Lei Chen, A. Guerin, Jipan Xie, E. Wu, A. Yu, S. Ericson, E. Jabbour (2012)
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysisCurrent Medical Research and Opinion, 28
R. Martin, A. Nelson, D. Magalí, C. Diana (2012)
PCN60 Cost Effectiveness of Nilotinib, Dasatinib and Imatinib as First Line Treatment of Chronic Myeloid Leukemia in Colombia 2011Value in Health, 15
T. Kim, M. Schwarz, H. Nogai, Peggy Grille, J. Westermann, U. Plöckinger, Doreen Braun, U. Schweizer, R. Arnold, B. Dörken, P. Coutre (2010)
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.Thyroid : official journal of the American Thyroid Association, 20 11
A. Bettiol, E. Marconi, N. Lombardi, G. Crescioli, F. Gherlinzoni, T. Walley, A. Vannacci, A. Chinellato, P. Giusti (2018)
Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid LeukemiaClinical Drug Investigation, 38
D. Stenehjem, Frederick Albright, K. Kuo, K. Raimundo, H. Bauer, P. Shami, M. Deininger, Lei Chen, D. Brixner (2014)
Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.Journal of the National Comprehensive Cancer Network : JNCCN, 12 8
D. Mitra, P. Trask, S. Iyer, S. Candrilli, J. Kaye (2012)
Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review studyInternational Journal of Hematology, 95
W. Edesa, R. Abdel-Malek (2015)
Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience.Journal of the Egyptian National Cancer Institute, 27 2
M. Saleh, S. Haislip, J. Sharpe, T. Hess, J. Gilmore, J. Jackson, K. Sail, S. Ericson, Lei Chen (2014)
Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community settingCurrent Medical Research and Opinion, 30
D. Pulte, B. Barnes, L. Jansen, N. Eisemann, K. Emrich, A. Gondos, S. Hentschel, B. Holleczek, K. Kraywinkel, H. Brenner (2013)
Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st centuryJournal of Hematology & Oncology, 6
F. Efficace, M. Baccarani, G. Rosti, F. Cottone, F. Castagnetti, M. Breccia, G. Alimena, A. Iurlo, A. Rossi, S. Pardini, F. Gherlinzoni, M. Salvucci, M. Tiribelli, M. Vignetti, F. Mandelli (2012)
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome studyBritish Journal of Cancer, 107
M. Almeida, L. Fogliatto, D. Couto (2014)
Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemiaRevista Brasileira de Hematologia e Hemoterapia, 36
R Hehlmann, A Hochhaus, M Baccarani (2007)
European Leukemia Net: chronic myeloid leukaemiaLancet, 370
E. Jabbour, H. Kantarjian, Dan Jones, Jenny Shan, S. O'brien, Neeli Reddy, W. Wierda, S. Faderl, G. Garcia-Manero, S. Verstovsek, M. Rios, Jordi Cortés (2009)
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.Blood, 113 10
S. Balabanov, Melanie Braig, T. Brümmendorf (2014)
Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia.Drug discovery today. Technologies, 11
M Wetzler, G Marcucci, CD Bloomfield (2011)
Harrison’s principles of internal medicine
Lucien Noens, Marie-Anne Lierde, Robrecht Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Eygen, K. MacDonald, Sabina Geest, Tara Albrecht, Ivo Abraham (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.Blood, 113 22
M. Payandeh, M. Sadeghi, Edris Sadeghi (2015)
Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran.Asian Pacific journal of cancer prevention : APJCP, 16 17
C. Schiffer (2007)
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.The New England journal of medicine, 357 3
T. Yoshizato, Y. Nannya, Y. Yoshiki, F. Nakamura, Y. Imai, M. Ichikawa, M. Kurokawa (2011)
Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemiaInternational Journal of Hematology, 93
E. Jabbour, J. Cortes, H. Kantarjian (2013)
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.Clinical lymphoma, myeloma & leukemia, 13 5
S. Goulden, F. Sutcliffe, A. Stevens (2012)
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.The Lancet. Oncology, 13 2
Background Chronic myeloid leukemia (CML) has a low incidence but a high burden of disease, and is treated with high-cost tyrosine kinase inhibitors (TKI). Objective To determine the time from the start of a first-line TKI until it passes to second-line, and to establish the reasons for the change of therapy time. Setting Patients with Philadelphia-positive CML treated with some TKI. Methods Retrospective cohort study, between January 1 2007 and July 31 2015, with information obtained from medical records, the time to change initial drugs to secondline therapy, and the reasons for change, were identified. Kaplan–Meier survival analysis was carried out. Main outcome measure A change in therapy to the secondline TKI and the final reason for the change of therapy. Results A total of 247 patients treated were found in 22 cities in Colombia with a mean age of 53.2 ± 15.2 years. The drug most used as initial therapy was imatinib; 53.8% of cases had to change to another TKI. 50% of patients changed therapy in 42 months, men in 24 and women in 67 months (95% CI 14.314–33.686; p = 0.001). Being male (OR 2.23; 95% CI 1.291–3.854; p = 0.004) and receiving hydroxyurea (OR 3.65; 95% CI 1.601–8.326; p = 0.002) were associated with a higher probability of switching to nilotinib or dasatinib, while receiving a new-generation TKI (OR 0.15; 95% CI 0.071–0.341; p < 0.001) reduced this risk. Conclusions A high proportion of patients needed to change to a second line with nilotinib and dasatinib management. It is necessary to obtain more real world evidence, to improve the effectiveness, adherence and safety of the treatment.
International Journal of Clinical Pharmacy – Springer Journals
Published: May 15, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.